TPCK

• Product Name Alternative:

  L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK

• UNSPSC Description:

  TPCK (L-1-Tosylamido-2-phenylethyl chloromethyl ketone; L-TPCK) is an effective serine protease inhibitor and also a blocker of the PDK1/Akt pathway. TPCK can modify the E7 protein in actively keratinocyte cells. TPCK can induce cellular apoptosis, suppress tumor growth, reduce hypoxic-ischemic brain injury in rat pups, and affect vascular permeability in inflamed rats[1][2][3][4][5].

• Target Antigen:

  Apoptosis; HPV; PDK-1; Ser/Thr Protease

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Apoptosis;Metabolic Enzyme/Protease;PI3K/Akt/mTOR

• Field of Research:

  Cancer; Infection; Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/tpck.html

• Purity:

  99.0

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC1=CC=C(C=C1)S(N[C@@H](CC2=CC=CC=C2)C(CCl)=O)(=O)=O

• Molecular Weight:

  351.85

• References & Citations:

  [1]H Stöppler, et al. The serine protease inhibitors TLCK and TPCK react with the RB-binding core of HPV-18 E7 protein and abolish its RB-binding capability. Virology. 1996 Mar 15;217(2):542-53.|[2]Patrícia de A Machado, et al. Effects of a Serine Protease Inhibitor N- p-Tosyl-L-phenylalanine Chloromethyl Ketone (TPCK) on Leishmania amazonensis and Leishmania infantum. Pharmaceutics.2022 Jun 29;14(7):1373.|[3]H Stöppler, et al. The serine protease inhibitors TLCK and TPCK react with the RB-binding core of HPV-18 E7 protein and abolish its RB-binding capability. Virology. 1996 Mar 15;217(2):542-53.|[4]M H LeBlanc, et al. N-tosyl-L-phenylalanyl-chloromethylketone reduces hypoxic-ischemic brain injury in rat pups. Eur J Pharmacol. 2000 Mar 3;390(3):249-56|[5]K Watanabe, et al. Vascular permeability changes by proteinase inhibitors in carrageenin-induced inflammation in rats. Agents Actions. 1986 Mar;17(5-6):472-7.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  402-71-1